Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion.

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.68% to $432.00 Tuesday, on what proved to be an all-around mixed trading ...

Vertex Pharmaceuticals reported disappointing Q1 revenue and earnings. The company also revealed it is temporarily pausing part of a phase 1/2 study of experimental cystic fibrosis drug VX-522.

In trading on Tuesday, shares of Vertex Pharmaceuticals, Inc. (Symbol: VRTX) entered into oversold territory, hitting an RSI reading of 28.4, after changing hands as low as $431.65 per share.

Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $4.06 per share for the first quarter of 2025, missing ...

In its first-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals Incorporated (NASDAQ ...

Vertex Pharmaceuticals VRTX will release its quarterly earnings report on Monday, 2025-05-05. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Vertex ...

Alphabet Inc (Symbol: GOOG) is off about 0.2%, and Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is lower by about 0.6%. For a complete list of holdings, visit the TQQQ Holdings page » The chart ...

Vertex Pharmaceuticals reported a slight increase in first-quarter sales, while profit fell due to higher operating expenses and an impairment charge tied to the discontinuation of a diabetes ...

Access detailed historical stock prices, including daily closing prices, for VRTX. Analyze past performance trends, track price movements, and explore historical data to inform your investment ...